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Abstract: Population extended life expectancy has significantly increased the risk of septic shock
in an ageing population. Sepsis affects roughly 20 million people every year, resulting in over
11 million deaths. The need for faster more accurate diagnostics and better management is therefore
paramount in the fight to prevent these avoidable deaths. Here we report the development of
a POC device with the ability to identify a broad range of pathogens on a lateral flow platform.
Namely Gram-positive and Gram-negative bacteria. The simple to use laboratory device has the
potential to be automated, thus enabling an operator to carry out solid-phase lysis and room
temperature RPA in situ, providing accurate results in hours rather than days. Results show there is a
potential for a fully automated device in which concepts described in this paper can be integrated
into a lateral flow device.
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1. Introduction
1.1. Sepsis
Sepsis has become one of the most abundant reasons for patients being admitted to an intensive
care unit (ICU) and for the rapid deterioration of health throughout a hospital stay. Sepsis is caused
by an unregulated immune response to localized infection [1,2] and without appropriate treatment
this response can advance throughout the body, leading to the immune system mistakenly attacking
healthy cells. This aforementioned dysregulation of the immune system can cause a deterioration of
organs and tissues, inhibiting responses and ultimately resulting in severe multi-organ failure and
death [3]. Annually, in the UK alone it is estimated that there are around 274,000 cases of sepsis [4],
with an approximate 28% mortality rate, surpassing lung cancer to become the second biggest cause
of death after cardiovascular disease [1]. The rise of sepsis cases was initially believed to be simply
the host’s responses to particular pathogens, however, there has been a far more complex interplay
between the root cause of the immune response and that of the host body, as explained by Gotts et al. [1].
In addition, the population extended life expectancy creates a demographic that is at high risk of
contracting severe infections [5]. In the last 25 years, the population of those over the age of 65 in the
UK has risen by 2.2%, resulting in 11.8 million older people who fall into the higher risk category [4].
With age, the immune system experiences a reduced production of essential adaptive immune cells and,
consequently, must work harder to fight off an infection, creating a generation of people who are unable
to respond to this type of immune challenge [5]. Both the elderly, and young children are susceptible
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to experience very serve forms of sepsis due to impaired T-cell activity and decreased expression of
immune system responses [5], resulting in cases of sepsis among neonates being misdiagnosed [6].
More recently in 2020 the often devastating and long-lasting effects of COVID-19 on the body has
increased the host’s susceptibility to sepsis resulting in a significantly increased number of cases.
Common indicators of COVID-19 infections include respiratory difficulties, with severe cases being
admitted into a hospital for pneumonia and other signs of damage in the majority of organs [7].
Both reports from China and the US have shown links between COVID-19 and potential sepsis cases,
with 75% of cases in the Seattle region alone accounting for a suppressed immune response [7] and
28% of cases in China experiencing severe heart damage, which often leads to a 5-fold increase in the
risk of death. [8] Patients with a compromised immune system—for instance, those with HIV/AIDS
and cancer patients undergoing chemotherapy—are more susceptible to experiencing severe forms of
sepsis and hospitalization [9,10]. In addition, cytotoxic chemotherapy causes immunodeficiency in
cancer patients and is associated with a much higher risk of bacterial or fungal infection that leads to
sepsis [11].
An expansive range of pathogens is often the source of onset sepsis [1]. The ever changing
adaption of sepsis also impacts the reported number of cases [12]. The origins of sepsis were initially
believed to be evoked by Gram-negative bacteria as a result of cells discharging endotoxins into the
bloodstream, which orchestrated a series of events yielding an immune response [13]. However
this theory is no longer considered true, with more recent studies [14] showing a wide range of
pathogens causing sepsis, with around 47% of cases originating from Gram-positive bacteria, 64% by
Gram-negative bacteria and 19% by fungus [15,16]. Viruses have also been shown to cause sepsis,
but the number of cases is much smaller, [16] and will therefore not be presented in this study. With this
in mind, a wide range of infections can be associated with sepsis, including predominantly pneumonia
(64%), bloodstream (15%) and infections in the abdomen, which, if left untreated, can cause them to
spread and develop into sepsis [17].
1.2. Diagnosis
A variety of different methods were established to determine the presence of sepsis. However,
the most common one used in early diagnosis was Systematic Inflammatory Response Syndrome
(SIRS) [18,19]. Unfortunately, this method was proved to be too sensitive and would often misdiagnose
other illnesses as sepsis. An alternative approach was therefore developed in 2007, known as sequential
organ failure assessment score (SOFA) [20]. This point-based system was more specific then SIRS
and allowed for an accurate diagnosis [20]. Patients with sepsis typically experience several different
ailments and, although SOFA was more accurate then SIRS, it became too complicated and often caused
delayed treatment. This was, therefore, modified to quick SOFA (qSOFA) to reduce complexity and
make diagnoses easier, allowing for greater use in a resource-limited setting [19]. Once SOFA or qSOFA
were preformed, further experiments could be conducted to determine the cause of sepsis [18]. This is
routinely carried out with the aid of blood cultures which are considered the “gold standard” [21].
However, blood culture results can take anything between 2–5 days, by which point the patients’
health would have deteriorated dramatically, leading to permanent damage and potential death [22].
Examples of POC devices used today include such methods as Septifast (SF) (Roche Diagnostics,
Mannheim, Germany) which has been designed to detect 25 different pathogens relating to sepsis using
whole blood samples. Detection takes place within 5 h, considerably faster than blood cultures [22].
Although much faster, a patient’s health can drastically deteriorate over a short period of time,
and hence a more rapid approach is often desired. Hence there is a clear need for fast reliable point of
care (POC) Sepsis detection.
1.3. Lateral Flow
Rapid testing has become key to treating sepsis cases correctly and, as such, a high demand for
POC devices has developed over the years [23]. These are near-patient rapid tests that can reduce the
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time between diagnosis and treatment, are low cost and easily operated by health care workers and
potentially people with a lack of background knowledge. These devices also often only require a small
sample from patients, making them desirable for neonatal care [24]. Sepsis POC has the potential to
improve the time from detection to the treatment of patients, allowing for a reduced death rate and to
prevent permanent damage to the organs [25]. Examples of lateral flow being used to detect sepsis can
be seen in [26,27], yet many do not target the broad range of pathogens that can lead to sepsis.
Within a nucleic acid lateral flow immunoassay, the signal is detected via a sequence containing
a tag, with the most common ones being fluorescence isothiocyanate [28] and biotin, [29] which are
complementary to either an antibody bound to the surface of the “test” point or complementary to a tag
that is labelled, allowing for visualization [30]. The most familiar method of amplification is polymerase
chain reactions; however, more recently isothermal amplification methods, including methods such
as recombinase polymerase amplification (RPA) [31] and loop-mediated isothermal amplification
(LAMP) [28], have been at the forefront of POC testing [31].
1.4. RPA Reactions
Recombinase polymerase amplification (RPA) was first introduced in 2006 by Pipenburg et al. [32]
to improve isothermal PCR methods within POC devices. The RPA reactions can circumvent fluctuating
temperatures that constrain PCR, running solely at 37 ◦C [32]. At 37 ◦C recombinase proteins interact
with primers present in the sample mixture, creating a recombinase primer complex that can read
across target DNA and bind accordingly, dismantling the hydrogen bonding between the double strand
nucleotides and replacing them with complementary regions of the recombinase primer complex [32].
This is then able to amplify accordingly without the aid of fluctuating temperatures to displace adjacent
strands [32,33]. Polymerase, similar to that in PCR, is then able to create a new DNA strand that is
complementary to the existing DNA. [34] The displaced DNA are stabilized using single-stranded DNA
proteins (gp32), typically found in the DNA repair systems of bacteriophages [35,36]. The advantages
of RPA reactions are that they are faster and require less energy to get similar results to a PCR
reaction with a detection limit of less than 10 copy numbers of DNA [37]. Although there are many
advantages of RPA, the reality of such mechanisms shows that there are limitations to this method [38].
Flexibility in the kit formulation to tailor for desired needs is difficult, with only one company, Twist Dx
(www.twistdx.co.uk; UK) having the rights to mass-produce such kits [32,38]. In addition, there are
issues in PCR and RPA, namely their inability to amplify in the presence of high concentrations of
genomic DNA without experiencing a large production of primer artefacts [32,39]. The inability
of RPA’s effectiveness in creating amplicons with a base pairing of greater than 300 should also
be considered [40]. Notwithstanding this, RPA reactions are one of the most robust and simplest
isothermal PCR reactions to use in comparison to other isothermal amplification methods.
Here, we demonstrate the use of RPA reactions on a solid phase surface. The integration of a
solid surface reaction, rather than liquid, allows for a more controlled exposure to contaminate and
a decreased time to result, which in the future will help to facilitate a potentially fully integrated
rapid test as represented in Figure 1. The RPA reactions were performed on cellulose paper and later
transferred onto lateral flow devices to be analyzed. Experiments were also conducted to prove that
cell lysis could also be performed on cellulose paper, allowing for further studies into the production
of a completely integrated solid phase device from sample to result. These methods have the potential
to be advantageous in resource limited setting, where the equipment for methods, such as PCR, are not
available and the risk of contamination can be higher.
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Figure 1. Lab-on-a-chip for solid phase-based lateral flow assay. (a) An illustration of solid phase lysis
taking place on cellulose paper. (b) Illustration of solid phase lysis paper being pressed against solid
phase RPA paper, allowing for RPA reactions to then take place. (c) Illustration of nucleic acid lateral
flow detection of products of solid phase RPA. (Adapted from Piepenburg et al. [32].)
2. Materials and Methods
2.1. Fabrication of Lateral Flow
First and foremost, the development of the target sequences for the nucleic acid-based detection,
are to be co sidered. Because sepsis is caused by such a broad range of pathogens, sequences that can
broadly pick up a specific group of pathogens are ideal. The gene sequence for RPOB [41] concerning
Gram-negative bacteria was chosen, MerA [42] for Gram-positive bacteria. Sequences were downloaded
from the GenBank®database (https://www.ncbi.nlm.nih.gov/GenBank/) and analyzed on BioEdit to
create a multiple sequence alignment. Primers were aligned to the guidelines of the TwistAmp®DNA
amplification kit (TwistDx, Ltd., Maide head, UK) and the optimal primer combination was obtained
via screening using basic local alignment search tool BLASTN ( ttps://blast.ncbi.nlm.nih.gov/Blast.cgi).
All oligonucleotides were synthesized by Eurofins Genomics.
2.2. Development of the Solid Phase RPA Reactions
Reagents for RPA reactions were supplied by TwistDx, Ltd., apart from template and primers—the
latter were purchased from Eurofins Genomic. In these experiments, nitrocellulose, cellulose and
polyvinyl difluoride (PVDF) were initially studied for their ability to retain proteins nd other reagents
within their pores. Only cellulose was continued onto experiments. To te t their ompatibility with RPA
reactio s, experiments were carri d out as follows: Cellulose (Whatmann®) was cut into thin strips of
20 × 5 mm and saturated with 0.5% bovine serum albumi (BSA, 50 µL) for 30 in. The cellulose was
then washed three times for five minutes n nuclease-free water and left t dry at room temperature for
1 h. Next, a master mix RPA reagents was m de up consisting of forwarding primer (1.2 µL, 10 µM),
reverse primer (1.2 µL, 10 µM), 12.5 µL of r action buffer, dNTP’s (4.6 µL, 10 µM) and 2.5 µL of 10 ×
p obe E mix [32], r ady to put onto the surface of the solid phase.
Each forward primer has either digoxigenin (DIG) or fluorescein (FAM), whilst each reverse primer
contains biotin (BIO). These labels allow for the amplified product to b detect d by the antibodi s
found on the surface of the l teral flow dev ce. A 25 µL s lution of “master mix” wa pipetted onto
the su face of cellulose and left for 30 min to dry [43]. Cellu os is then sealed insid a chamber
made from a combination of parafilm and Po ytetrafluoroethylene (PTFE). PTFE acted as a sealing
ta preventing moister from being lost during a reaction, whilst parafilm wa us d to prevent the
PTFE fro directly sticking to the cellulose strip [44]. These prepared strips were then placed at 4 ◦C
until ready for us . The lysis pads were constructed as follows: cellulose was cut into 20 × 5 mm
strips. A mixture of (4-(2-hydroxyethyl)-1-piperazine thanesulfonic acid) (HEPES) (1 mM, pH 8),
Ethylenediaminetetra cetic acid (EDTA) (500 mM), nonyl phenoxypolyethoxylethan l (NP-40) (10%)
and 2,5-Dimethoxy-4-chloro amphetamine (DOC) (10%) were added together in d 2O [45]. Next,
25 µL of this mixture was added to the surface of cellulose and left to dry at ro m temperature for 1 h.
Once dry, the cellulose strips were stored at 4 ◦C until ready for use.
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2.3. Lysis of Pathogens
For comparison, each set of experiments were carried out via both solid and liquid phase.
For liquid-phase, Escherichia coli (ATCC® 700926™) and bacillus subtilis (ATCC® 6051™) were picked
and cultured in 5 mL broth for 16 h at 37 ◦C. After 16 h, all broths were spun down for 1 min at 10 g
to remove liquid and leave the remaining cells. The cells were re-suspended in 200 µL of PBS on ice
and then spun for a further 1 min at 37 ◦C, after which the PBS was removed. Cells were suspended
in 200 µL of lysis solution [45], as previously described, and left for 20 min at 37 ◦C. On completion,
the lysis solution was cooled on ice for 10 min and centrifuged for 1 min at 10 g to remove cell debris.
The supernatant was removed and 250 µL ice-cold ammonium acetate (7.5 M) was added and held on
ice for a further 10 min to precipitate proteins out of solution and centrifuged for 1 min at 10 g and
supernatant was poured off into clean Eppendorf [45]. To remove any remaining proteins present,
a solution of chloroform:butanol (24:1) was added and gently mixed to separate DNA and proteins into
their miscible solutions, causing the aqueous layer (top layer) to contain DNA, whilst the bottom layer
contains remaining proteins from the lysed cell [46,47]. Once settled, the aqueous layer was removed
and, to this layer, an equivalent of 0.54 to solution ice-cold propan-2-ol was added and inverted gently
for 60 s until a white solid was formed. The remaining solution was spun for 20 s at 10 g, producing a
pellet of DNA at the bottom of the Eppendorf [46]. The supernatant was removed, and 70% ice-cold
ethanol was used to wash the DNA. Once the ethanol had been poured off, the DNA was allowed
to dry at room temperature. This was done by partially sealing the Eppendorf with parafilm with
holes pierced in it to allow ethanol to escape whilst reducing the chance of contamination. The solid
was re-suspended in 200 µL of ddH2O and the concentrations of the resulting DNA were confirmed,
and the mixture was then diluted in a range between 100–10 ng/µL, depending on how successful
extraction was. DNA was then stored at −20 ◦C until needed.
The solid-phase lysis reactions were similar to the liquid phase, however after pellets were formed
and washed with PBS, these were then re-suspended in 500 mM PBS solution and 50 µL was then
placed directly onto a pre-made cellulose strip as previously described and impregnated with a lysis
solution (25 µL) [44]. The strip was then sealed in parafilm and incubated at 37 ◦C for 30 min to prevent
the surface from drying out. Parafilm was then removed and placed in an Eppendorf and spun for
1 min at 10 g. Cellulose was then removed and a further 50 µL of 500 mM PBS buffer was added to it,
surrounded by parafilm, sealed inside two pieces of PTFE and incubated for 10 min at 37 ◦C. This was
done to collect whatever remained on the surface of the cellulose. After 10 min, the cellulose strips
were then added to the Eppendorf and spun again for 1 min at 10 g to extract any remaining product
from the surface of the cellulose. The cellulose was then removed from the combined solutions of
product and the liqueur was treated and the product purified as previously described. The purified
product was taken for nanodrop reading to determine the DNA concentration/purity. These methods
were also compared with sonication, which was used as a standard.
2.4. Primer Design
To establish nucleic acid detection using RPA reactions, the starting point was to identify
target gene sequences. Sepsis is caused by a broad range of different pathogens, [48] each
with its unique gene sequences. For a simplistic approach, pathogens causing sepsis were
split into two categories—Gram-negative bacteria and Gram-positive bacteria and the core gene
sequences—established to pick up a broad range of pathogens within each group, whilst avoiding
the detection of other pathogens, to increase specificity [49]. For Gram-negative bacteria, the gene
sequence RPOB (reference sequence: NC_000913.3) [41], a basic transcription gene was chosen, and for
Gram-positive bacteria, mercury reductase (MerA, reference sequence: CP008814.1) [42] was used.
Each gene was obtained from the GenBank database (https://www.ncbi.nlm.nih.gov/genbank/) and
using BioEdit multiple alignments was performed on each gene sequence comparing it between
categories previously described. Primers were designed based on the guidelines provided by the
TwistAmp DNA amplification kit (TwistDx Ltd., Maidenhead, UK) and an optimal primer combination
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was obtained by screening via basic local alignment search tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi)
and physical testing. All primers were purchased from Eurofins genomic, as described in Section 2.1.
2.5. PCR
All PCR reactions were conducted to prove that the RPA primers designed were able to amplify
the desired sections of DNA. The PCR reactions were carried out as follows: to 12.5 µL of superfi
master mix (Invitrogen), 1.25 µL of forwarding (10 µM) and 1.25 µL of reverse primer (10 µM) were
added and mixed briefly. Following this, 1 µL of 10 ng/µL of DNA was added and again briefly mixed.
The mixtures were then placed in a PCR machine and run in a two-step cycle rather than three-step.
This was because, although PCR experiments were run, the primers used were RPA primers, and hence
were twice the size and did not require specific temperatures [32]. Reaction conditions for amplification
were 95 ◦C for 2 min, followed by cycling conditions of 94 ◦C for 30 s and 72 ◦C for 30 s, with a final
extension of 72 ◦C for 5 min. All amplifications were analyzed on 2% agarose gels which ran for 80 min
at 50 V. Amplification products were detected using ethidium bromide.
2.6. RPA
All materials for RPA reactions, including buffers and reagents, were supplied by TwistDX,
UK. Genomic DNA strands were collected from either solid phase or liquid phase chemical lysis,
as previously described in Section 2.2. The resulting DNA was diluted to 10 ng/µL with nuclease-free
water. Each mixture contained the following: forward primer (1.2 µL, 10 µM), reverse primer (1.2 µL,
10µM), 12.5µL of reaction buffer, dNTP’s (4.6µL, 10µM) and 2.5µL of 10× probe E mix [32]. These were
briefly vortexed and, following this, 1.25 µL of 20 × core reaction mix was added and pipetted gently.
Next, 10 ng/µL of the template and 1.25 µL of MgOAc were added to the mixture, then vortexed briefly
to start the reaction. Samples were then incubated at 37 ◦C for 20 min. After 4 min, samples were
briefly taken out and shaken and returned to the incubator. Samples were then immediately frozen at
−80 ◦C for 10 min. The samples were defrosted ready for use using binding buffer supplied in GeneJET
PCR purification kit at a 1:1 ratio and isopropanol on a 0.5:1 ratio [50]. The mixture was pipetted a few
times to mix and then added to a purification column supplied from GeneJET. Columns were spun at
10 g for 1 min and the flow-through discarded. Columns were then washed with 100 µL of ice-cold
wash buffer (GeneJET) and spun again at 10 g for 1 min with the flow-through discarded. This was
repeated twice with a final third spin without any additional wash through to remove any excess wash
buffer. Finally, a new clean Eppendorf was used, and the column was added to it. Next, 10 µL of
elution buffer (GeneJET) was added to the column and spun for 1 min at 10 g. Resultant products were
then either used in lateral flow devices or added to polyacrylamide gels.
The solid-phase reactions used the same materials as the liquid reactions with the cellulose
used being prepared the same way as previously described above. However, after the addition,
reaction buffer, dNTP’s, 10 × probe E mix, primers and 20 × core reaction mix were added to an
Eppendorf and spun down. These were then added to cellulose at –80 ◦C for 10 min. Following this,
they were freeze-dried, allowing for consistent drying along the entire surface of the cellulose [51].
Once fully dry, strips were left at −20 ◦C until ready for use. Next, 25 µL of nuclease-free water
containing template DNA and 1.25 µL of MgOAc was made up in an Eppendorf and mixed briefly.
This was then added to the surface of the dried cellulose, which was sealed in parafilm and PTFE and
incubated at 37 ◦C for 30 min. Next, the parafilm and PTFE were removed and cellulose strip was
spun for 1 min at 10 g. Cellulose was then soaked with 50 µL of nuclease-free water, left to sit for a
further 10 min, and then spun for 10 min at 10 g. The resultant product was then frozen at −80 ◦C for
10 min. Samples were defrosted with binding buffer and isopropanol in a 1:0.5:1 ratio and spun in a
purification column (GeneJET) at 10g for 1 min and the flow-through was discarded. The solution
was then washed with ice-cold wash buffer, spun for 1 min at 10g. This was repeated twice and the
flow-through discarded. Finally, the column was added to a clean Eppendorf and 10 µL of warm
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elution buffer was added to the column. These were then spun for 1 min at 10 g and either analyzed
via polyacrylamide gel or on the lateral flow device.
Solid-phase lysis was repeated as described above and, following this, the parafilm was removed
and lysis paper was pressed onto the surface of the RPA solid phase. These two pieces of cellulose,
one from the lysis reaction and one from the RPA reaction, were then sealed together with parafilm
and PTFE, as previously described, and left to incubate at 37 ◦C for 30 min. The resulting product was
then extracted off the paper via centrifugation and added to the binding buffer and vortexed briefly.
Next, 75 µL of product/buffer was then added to the lateral flow device via the sample pad and left to
run for 10 min. The results were observed after 10 min. All experiments were repeated in triplicate.
3. Results and Discussion
In addition to the standard technique provided by TwistDx, the RPA reactions were performed
via the novel solid-phase technique, as explained in Section 2.4. The results were compared concerning
both the sensitivity and time-to-results, as well as cross-reactivity. For all tests, DNA concentrations
were prepared from stock solutions that were previously extracted through sonication or chemical
lysis, as previously described, and diluted down using nuclease-free water.
3.1. Lysis Reactions
All lysis reactions were compared using standard sonication methods along with chemical lysis.
This system was designed from a variation of chemical lysis known as radioimmunoprecipitation
(RIPA) buffer [45]. The RIPA buffer circumnavigated the demand for a clean-up step between lysis and
amplification and ultimately led to a reduced chance of external contamination whilst still being able
to produce reliable results. Each sample was placed in 1% agarose gel containing ethidium bromide
and analyzed via agarose gel, which can be seen in Figure 2.
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The results, as shown in Figure 2, showed that, although lysis was apparent for solid-phase lysis,
it was unable to break down as many pathogens, most likely due to the restricted flow of reagents on
the solid surface [52]. Results from the nanodrop also indicated a lower yield of DNA extracted via
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solid-phase lysis, as shown in Figure 3. It should be noted that, when integrating the lysis step with
the RPA reactions, however, issues occurred, which are discussed further in Section 3.4.
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3.2. PCR Reactions
The PCR reactions were initially conducted to confirm that the primer designs were able to
bind to genomic DNA extracted from pathogens. The results showed that the RPA primers could
be successfully used with PCR reagents (data not shown) allowing for exp riments to be continued
onto RPA.
3.3. Liquid RPA Reactions
Liquid RPA was conducted to prove the effectiveness of the primers designed in RPA reactions and
to compare the data sets between liquid and solid-phase results. Although reactions initially worked,
analysis via polyacrylamide gels showed that the samples created a bright shadow as they passed
through the gel, as well as leaving a larger signal at the very top of the gel. It was concluded that the
bright shadow seen at the top of the gels could indicate the remaining recombinase–primer complex
present in the sample, thus being too big to pass through the gel [35]. To improve the gels, GeneJET PCR
purification kits were used to remove remaining proteins from RPA reactions, allowing for much
clearer signals, as shown in Figure 4 [35].
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3.4. RPA Reactions with Contaminates
The effects of lysis on RPA reactions were determined via “spiking” standard liquid reactions
with individual RIPA buffer reagents in addition to a combination of reagents. HEPES (1 M), Na-DOC
(10%), EDTA (500 mM) and NP-40 (10%) [45] were each added by substituting the volume of water
added to each mixture, making the final concentration of reagents equivalent to that of a standard RIPA
reaction. Although HEPES, EDTA and NP-40 showed little effect on RPA reactions, Na-DOC was found
to hinder the RPA reactions. The concentration of Na-DOC was therefore adjusted between 2–10%,
and initial findings demonstrated that RPA reactions experienced hindrance at a concentration greater
than 6%. The literature has also shown that some detergents, such as SDS, also have similar inhibitory
effects to amplification [53]. To accommodate the Na-DOC, concentrations were adjusted accordingly.
For completeness, the RPA reactions were also spiked with blood (Thermo Scientific Oxoid
SR0050C) to replicate POC use, was used to dilute 10 ng of pathogenic DNA creating a concentration
range between 10 and 2 ng. The whole blood samples did not affect amplification, [40] with only a
small decrease in amplification seen at 2.5 ng/µL of pathogenic DNA (data not shown).
3.5. Solid-Phase RPA Reactions
Initial experiments tested the compatibility of RPA reactions with a solid surface. A master mix,
as previously described [32], was made up and pipetted onto the surface of cellulose paper. Primers and
template were added together and mixed and pipetted onto the solid surface for 20 min at 37 ◦C to
mimic a standard RPA reaction. Next, 2% BSA was used to prevent none-specific binding; the BSA was
coated and dried onto the solid phase before proteins were added. [54] Experiments were repeated in
the presence of the blocking agent, which proved valuable, resulting in the efficient removal of proteins
bound to the surface [55].
During solid-phase RPA, reagents supplied by TwistDx, dNTP’s and forward/reverse primers,
outlined in Section 2.2, were added together in a “master mix” and added to the surface of each solid
phase surface and immediately frozen at −80 ◦C. Following this, the surface was freeze-dried for
10 min. Initially, pads were placed in the freeze dryer and left until completely dry; however, it was
noted that as the surface dried the solution concentrated towards the center of the pad, suggesting
that there would be an unequal distribution of reagents on the surface. This has been acknowledged
before in many papers and is usually provoked by uneven temperature distribution on the surface
of the material, creating varying drying times [51,56]. Therefore, the method was adapted, with a
brief freezing step at −80 ◦C to allow for a constant temperature on the surface and allow for even
drying speed [50]. Sudden temperature changes also reduced the chances of potential contaminates
from interacting with the RPA reagents on the surface, and thus potentially causing a reaction to take
place. Once dry, a mixture consisting of DNA, MgOAc and nuclease-free water was pipetted onto the
surface, the solid phase was then sealed with parafilm and PTFE. Results were analyzed via either
polyacrylamide gels or on the lateral flow devices. Reactions were performed at the same temperature
and time to standard liquid reactions; however, at 20 min the signal produced on the polyacrylamide
gel was not strong enough to draw any meaningful conclusions, thus the time of 20 min was increased
to 30 min to allow for complete use of all reagents in the reaction. This was postulated to be needed to
allow for the reactions to take place on the solid surface as, unlike liquid reactions, there is a restricted
movement due to the presence of the solid phase. After 30 min, the product was removed via centrifuge
and collected in an Eppendorf. The solid phase was then saturated further with nuclease-free water to
release any product still left on the surface and centrifuged off and analyzed via polyacrylamide gel or
on the lateral flow device, as can be seen in Figure 5.
Figure 5 shows Gram-negative bacteria and Gram-positive bacteria were amplified accordingly,
hence both reactions were deemed to be successful. To demonstrate that both solid-phase lysis and RPA
could be carried out in succession, lysis was performed on a solid surface. Once 20 min was completed,
this “lysis phase” was pressed against a pre-treated RPA solid phase and sealed in PTFE to prevent it
from drying out. Products were purified and analyzed via either lateral flow or polyacrylamide gel to
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prove that the desired reactions had taken place. Results showed that amplification was successful
with this method and produced results similar to that of just the solid phase RPA reaction. The set-up
also illustrates that the integration of two or more of these reactions may be suitable for integration
into a lateral flow (data not shown).Sensors 2020, 20, x FOR PEER REVIEW 10 of 15 
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3.6. Integration with Lateral Flow Device
All solid-phase work was c rried out using lateral flow devices supplied by Abingdon health.
Antibodies on these lateral flow devices w e complementary to those supplied in the device and allowed
for the successful binding between lateral flow device and the prod ct produced. Once solid-p a
lysis and RPA were completed, the resulting solutions were extracted from cellu ose and adde to the
running buffer. This mixture of running buffer and RPA r action was then placed on the sample pa
the lateral flow dev ce and un for 10 min, after which results were photographed, as shown in Figure 6.
The results showed hat reactions run on solid phases were able to be run on lateral flow devices.
Reactions were successful for Gram-negative and Gram-positive primers as illustrated in Figure 6.
With these results in mind, DNA collected from solid-phase lysis reactions were diluted down
using nuclease-free water and solid phase RPA reactions were run. Results from these can be seen in
Figure 7 with a limit of detection of 2 ng/nL DNA per reaction. A slight shadow can be seen at the top
of the gel, which could indicate the presence of a recombinase primer complex still within the sample.
Within Figure 7 the control lane 1 on the gel shows no amplification illustrating that there were no
contaminants in the sample. Lane 2 shows amplification as well as artefacts being produced. This can
either be from contamination or the RPA reaction amplifying on mismatching complementary strands.
Lane 6 is the brightest band due to this having the largest concentration of DNA present. This band also
experiences artefacts at approximately 200 bp, which could be due to a large amount of DNA present
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in the sample, allowing for more potential mismatching and amplification. To conclude, a range of
between 100 ng to 0.1 ng/µL was tested which can be seen on both polyacrylamide and lateral flow
devices. Anything above can potentially hinder RPA reactions [40].Sensors 2020, 20, x FOR PEER REVIEW 11 of 15 
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4. Conclusions and Future Work
Accurate and fas POC devices for the d tection and c rrect diagn sis of sepsis will become the
forefront in the improv ment of the tr atment of patients (their ubsequent recovery rate) an th battle
agains the ever increasing number f sepsis cases worldwide. Here, we have described the use of ll
steps to ards the det ction of pathogenic DNA via soli -phase lysis, amplification and subsequ
detectio , which in the future can be d veloped into a fully int grated device. The nsemble was able
t detect va ious pathogens that commonly induce sepsis, i cluding E. coli and B. subtilis. In ddition
to this, RIPA buffer reagents w re used to br ak open the cells and extract t e DNA, and s
sh w not to affect the RPA reactio —with exception of Na-DOC which demo trated mild disruption
to reactions. Solid-phase RPA reacti ns were abl to detect as little as 2 ng/µL of DNA. This pap r also
hows the succes of a step by step process of lysis followed by RPA, both carried ut on a solid phase.
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However further work would need to be conducted in order to merge methods described with lateral
flow devices.
Future work would look into the detection of fungal pathogens that also cause sepsis to create a
device that would be able to detect the three major types of pathogen that can induce a septic response.
A complete evaluation of the precision and accuracy of the ensemble will also need to be carried out in
order to ensure that any arising false positive and negative results will be reduced on a larger sample
set. However, in essence, the ensemble shows much promise towards a fully integrated analytical test
with the potential to integrate tests done in this paper with lateral flow devices to identify pathogens
in a blood sample in under an hour without the need for expensive equipment.
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